Last checked at 22 Sep 2020 21:17
IN BRIEF: Immupharma Repays Lind Global Convertible Security
IN BRIEF: Immupharma Repays Lind Global Convertible Security
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Immupharma Share News (IMM)
IMM Share
Price
IMM Share
News
IMM Share
Chat5
IMM Share
Trades2
IMM
Live RNS1
IMM Share
Charts
IMM Level 2
Console
IMM Live
Share Price
IMM Broker
Ratings
IMM Directors
Deals
IMM Financial
Diary
IMM
Fundamentals
IMM Short
Positions
IMM
Media
Immupharma Information
Share Price Information for Immupharma (IMM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
2.24
Bid:
2.20
Ask:
2.27
Change:
0.00 (0.00%)
Spread:
0.07 (3.182%)
Open:
2.24
High:
0.00
Low:
0.00
Prev. Close:
2.24
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.11 Sep 2020 14:09
IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission
IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission
Read more11 Sep 2020 12:17
ImmuPharma confirms continued FDA delays for Lupuzor
(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.
Read more2 Sep 2020 11:18
Immupharma Raises GBP6.5 Million In Oversubscribed Placing
Immupharma Raises GBP6.5 Million In Oversubscribed Placing
Read more2 Sep 2020 09:25
Immupharma raises £6.5m in oversubscribed placing
(Sharecast News) - Drug discovery and development firm Immupharma has raised £6.5m, before fees, via an oversubscribed placing of 59.09m ordinary shares.
Read more27 Jul 2020 17:50
IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor
IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor
Read more27 Jul 2020 15:15
ImmuPharma clears 'important' regulatory hurdle for Lupuzor trial
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced what it called "an important regulatory milestone" on Monday, in preparation for the new optimised international phase 3 trial of 'Lupuzor' for the autoimmune disease systemic lupus erythematosus.
Read more11 Jun 2020 16:17
UK Shareholder Meetings Calendar - Next 7 Days
UK Shareholder Meetings Calendar - Next 7 Days
Read more11 Jun 2020 13:53
Immupharma Gets Over USD6 Million Investment From US Healthcare Funds
Immupharma Gets Over USD6 Million Investment From US Healthcare Funds
Read more14 May 2020 17:13
UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand
UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand
Read more1 May 2020 09:51
ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial
ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial
Read more31 Mar 2020 07:31
ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion
ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion
Read more30 Mar 2020 16:18
ImmuPharma raises ?1.5m to fund development programmes
(Sharecast News) - Drug discovery and development company ImmuPharma announced subscriptions to raise ?1.5m through the issue of 15 million new ordinary shares at a price of 10p each on Monday.
Read more28 Feb 2020 12:06
Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float
Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float
Read more6 Feb 2020 15:54
ImmuPharma and Avion to proceed with Lupuzor phase 3 trial
(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its activities with Avion Pharmaceuticals on Thursday, following the licence and development agreement it signed with Avion in November for the exclusive rights to 'Lupuzor' in North America.
Read more